Treatment of gastric cancer

Orditura, Michele; Galizia, Gennaro; Sforza, Vincenzo; Gambardella, Valentina; Fabozzi, Alessio; Laterza, Maria Maddalena; Andreozzi, Francesca; Ventriglia, Jole; Savastano, Beatrice; Mabilia, Andrea; Lieto, Eva; Ciardiello, Fortunato; Vita, Ferdinando De

doi:10.3748/wjg.v20.i7.1635

Cited by 549 publications

(460 citation statements)

References 104 publications

Supporting

Mentioning

433

Contrasting

Unclassified

Order By: Relevance

“…Tumors located in the distal part of the stomach are commonly treated by subtotal gastrectomy and reconstruction of digestive continuity. However, tumors located at the middle or proximal (cardia) part of the stomach may require total gastrectomy or esophagogastrectomy, if extended into the lower esophagus, resulting in a relatively worse prognosis [39][40][41][42]. Previous studies have shown that patients from Western countries have a significantly higher proportion of cardia tumors, while patients in Asia have a higher proportion of non-cardia gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

Examining the gastric cancer survival gap between Asians and whites in the United States

et al. 2016

View full text Add to dashboard Cite

Background Globally, Asian countries bear a disproportionate gastric cancer burden. Asian Americans, the fastest growing minority population in the US, have higher gastric cancer survival than non-Hispanic whites (NHWs) despite higher incidence. Benefitting from uniform cancer registry standards within the US, we examine for the first time the heterogeneity in the Asian American population, which may elucidate the causes of these disparities. Methods SEER gastric cancer data from 2000 to 2012 were used to calculate 5-year survival estimates for NHWs and the six largest Asian ethnicities. Multivariate analyses were performed to identify critical prognostic factors and survival disparities between Asian groups and NHWs. Results We analyzed 33,313 NHW and 8473 Asian gastric cancer cases. All Asian groups had significantly higher 5-year survival than NHWs, at 29.8%. Among Asians, Koreans and Vietnamese had the highest and lowest survival, at 45.4% and 35.7%, respectively. The Korean survival advantage was largely attributable to relatively high proportions of localized stage and low proportions of cardia tumors. After adjusting for major prognostic factors, the survival disadvantage of NHWs, while attenuated, remained significant in comparison to all Asian groups (HR: 1.33, 95% CI: 1.24-1.43; reference: Korean). The survival disparities within the Asian groups vanished with adjustment. Conclusions This study characterizes distinctive gastric cancer survival patterns among the six major Asian groups and NHWs in the US. The favorable survival for Koreans is largely attributable to specific clinical factors, particularly stage at diagnosis. The causes of the survival disadvantage for NHWs remain elusive.

show abstract

Section: Discussionmentioning

confidence: 99%

Examining the gastric cancer survival gap between Asians and whites in the United States

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The treatment of gastric cancer currently involves combinatorial therapies, including surgery, chemotherapy and radiotherapy; however, long-term survival rates remain relatively low (3,23). TNM classification based on the clinicopathological characteristics of tumors; including local invasive depth, lymph node involvement, and distant metastasis is the current gold standard for prognosis prediction and available Table II.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of HS6ST2 is associated with poor prognosis in patients with gastric cancer

Jin

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. The purpose of the present study was to investigate the clinical significance of the expression of heparan sulfate 6-O-sulfotransferase 2 (HS6ST2) in gastric cancer (GC). The Affymetrix GeneChip ® Human Genome U133 Plus 2.0 Array (Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used to identify differentially expressed genes in GC tissues vs. adjacent non-tumor gastric tissues. Candidate genes were further verified by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunohistochemistry (IHC). In addition, an independent dataset was obtained from the Gene Expression Omnibus, and a survival analysis was performed. Microarray analysis demonstrated that HS6ST2 was upregulated (>12-fold) in GC tissues compared with that in adjacent non-tumor tissues. RT-qPCR and IHC analysis of HS6ST2 in GC tissues and adjacent non-tumor tissues confirmed the microarray data. Furthermore, a positive association was demonstrated between HS6ST2 overexpression with the depth of tumor invasion, distant metastasis, and tumor-node metastasis stage. Survival analysis revealed an association between patients with increased expression of HS6ST2 and a poor prognosis of gastric cancer. Cox regression analysis indicated that the expression of HS6ST2 was an independent negative prognostic factor for GC. The expression of HS6ST2 in GC was significantly associated with specific clinicopathological parameters and prognosis of disease, thus we propose that HS6ST2 may represent a novel biomarker for GC.

show abstract

“…Despite developments in surgery, chemotherapy and radiation therapy, the prognosis of gastric cancer at advanced stages remains unsatisfactory, primarily due to tumor recurrence, local invasion and metastasis (5). The 5-year survival rate of patients with gastric cancer is <10% (6). Understanding the molecular mechanisms underlying the regulation of gastric cancer occurrence and development is necessary in order to identify novel and effective therapeutic methods to improve treatment outcome.…”

Section: Introductionmentioning

confidence: 99%

Microrna-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway

2018

View full text Add to dashboard Cite

Abstract. Gastric cancer is the fourth most common cancer and the second most frequent cause of cancer-associated mortality in the world. Previous studies have revealed that expression levels of microRNAs (miRNAs) are associated with the initiation and progression of several types of cancer, including gastric cancer. Previous studies have demonstrated that the abnormal expression of miRNA-136 may serve a function in the progression of several types of human cancer. However, the expression pattern of miR-136, its functions and underlying molecular mechanisms in gastric cancer remain unresolved. In the present study, it was revealed that the expression of miR-136 was aberrantly up regulated in gastric cancer tissues and cell lines. The suppression of miR-136 was able to inhibit proliferation and invasion in gastric cancer cell lines. Furthermore, phosphatase and tensin homolog (PTEN) was identified as a direct target gene of miR-136 in gastric cancer. PTEN was under expressed in gastric cancer tissues compared with non-tumor gastric tissues, and PTEN expression was negatively correlated with miR-136 expression. Furthermore, PTEN overexpression mimics the effects of miR-136 knockdown on gastric cancer cells. Additionally, miR-136 under expression decreased phospho-(p) AKT expression, but did not affect AKT expression in gastric cancer cells. In conclusion, the data of the present study suggest that miR-136 acts as an oncogene in gastric cancer via regulation of the PTEN/AKT/p-AKT signaling pathway and may potentially serve as a novel therapeutic target for the treatment of gastric cancer.

show abstract

Treatment of gastric cancer

Cited by 549 publications

References 104 publications

Examining the gastric cancer survival gap between Asians and whites in the United States

Examining the gastric cancer survival gap between Asians and whites in the United States

Overexpression of HS6ST2 is associated with poor prognosis in patients with gastric cancer

Microrna-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway

Contact Info

Product

Resources

About